We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

603939:SSEYifeng Pharmacy Chain Co Ltd Class A Analysis

Data as of 2026-06-14 - not real-time

CN¥21.75

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Yifeng Pharmacy Chain is trading at CNY 21.75, comfortably above its 20‑day SMA of 20.99 but still below the 50‑day and 200‑day SMAs, indicating short‑term momentum yet a longer‑term bearish bias. The MACD line sits above its signal line, producing a bullish histogram of 0.157, while the RSI of 53 suggests neutral pressure. Valuation metrics are attractive: the DCF‑derived fair value of CNY 29.99 far exceeds the current price, and the trailing P/E of 15.5 is well under the industry average of 24.8. The company delivers a solid 3.22% dividend yield with a modest payout ratio of 50%, backed by ample cash of CNY 9.35 bn and a manageable debt‑to‑equity of 33%. Profitability is decent, with ROE at 15.2% and operating margins around 12%, though revenue growth is modest at just 1.3%. Market sentiment is extremely bullish, reflected by a Fear‑Greed Index of 89.86 (Extreme Greed)**, but the stock faces high 30‑day volatility of 33% and a recent max drawdown near ‑25%.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bullish MACD crossover with positive histogram
  • Price above 20‑day SMA providing near‑term support
  • High market volatility and bearish longer‑term SMA alignment

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Significant undervaluation versus DCF fair value
  • Strong cash position and low debt‑to‑equity ratio
  • Attractive dividend yield with sustainable payout

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Stable earnings and solid ROE in a growing healthcare sector
  • Consistent dividend policy supporting income investors
  • Long‑term demographic tailwinds for pharmaceutical retail in China

Key Metrics & Analysis

Financial Health

Revenue Growth1.30%
Profit Margin7.05%
P/E Ratio15.5
ROE15.18%
ROA5.63%
Debt/Equity33.10
P/B Ratio2.2
Op. Cash FlowCN¥3.3B
Free Cash FlowCN¥2.2B
Industry P/E24.8

Technical Analysis

TrendBearish
RSI53.1
SupportCN¥19.62
ResistanceCN¥22.85
MA 20CN¥20.99
MA 50CN¥22.35
MA 200CN¥23.52
MACDBullish
VolumeDecreasing
Fear & Greed Index89.86

Valuation

Fair ValueCN¥29.99
GradeUndervalued
TypeValue
Dividend Yield3.22%

Risk Assessment

Beta0.00
Volatility33.07%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.